1. Induced Disease Models Products Immunology/Inflammation Apoptosis
  2. Immunology and Inflammatory Disease Models COX Apoptosis
  3. Hapten
  4. Diclofenac

Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.

For research use only. We do not sell to patients.

CAS No. : 15307-86-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
5 g In-stock
10 g In-stock
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 24 publication(s) in Google Scholar

Other Forms of Diclofenac:

Top Publications Citing Use of Products

    Diclofenac purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Oct 11;23(20):12066.

    KATOIII and KATO/DDP were treated with different concentration of Diclofenac (DCF) (0–1000 µM) for 48 h, and cell viability was assessed.

    Diclofenac purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Oct 11;23(20):12066.

    The KATO/DDP cells were treated with Cisplatin alone or cisplatin in combination with Diclofenac (DCF) at 10 or 20 µM for 24 h, at 37 °C. The apoptosis cells were detected by using annexin V and PI staining and analyzed by flow cytometer.

    Diclofenac purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Oct 11;23(20):12066.

    The combination effect of Diclofenac (DCF) (0, 5, 10, 20 μM) and Cisplatin on the expression of cleaved PARP in KATO/DDP cells was examined by Western blot analysis.

    Diclofenac purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Oct 11;23(20):12066.

    The formation of autophagic vacuoles in KATO/DDP cells increased from 27% to 39% and 45% in cotreatments involving cisplatin and Diclofenac (DCF) at 10 and 20 μM, respectively, when compared with treatment of cisplatin alone.

    View All COX Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3].

    IC50 & Target[1][2]

    Human COX-2

    1.3 nM (IC50, in CHO cells)

    Human COX-1

    4 nM (IC50, in CHO cells)

    Ovine COX-2

    0.84 μM (IC50)

    Ovine COX-1

    5.1 μM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    CHO IC50
    4 μM
    Compound: Diclofenac
    TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells
    TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells
    [PMID: 10991954]
    Erythrocyte IC50
    0.942 μM
    Compound: Diclofenac
    Anti-inflammatory activity in human RBC assessed as membrane stabilization
    Anti-inflammatory activity in human RBC assessed as membrane stabilization
    [PMID: 28818769]
    HEK293 EC50
    56 μM
    Compound: DCF
    Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay
    Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay
    [PMID: 30878828]
    HEK293 IC50
    > 500 μM
    Compound: diclofenac
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    [PMID: 23241029]
    HUVEC IC50
    0.75 mM
    Compound: Diclofenac
    Antiinflammatory activity in HUVEC assessed as inhibition of LPS-induced ICAM1 expression by cell-ELISA
    Antiinflammatory activity in HUVEC assessed as inhibition of LPS-induced ICAM1 expression by cell-ELISA
    10.1039/C0MD00262C
    L1.2 IC50
    12 nM
    Compound: 1
    Inhibition of wild type CXCR1 transfected in mouse L1.2 cells assessed as inhibition of CXCL8-induced cell migration pretreated for 15 mins measured after 4 hrs
    Inhibition of wild type CXCR1 transfected in mouse L1.2 cells assessed as inhibition of CXCL8-induced cell migration pretreated for 15 mins measured after 4 hrs
    [PMID: 19560921]
    L1.2 IC50
    > 10 μM
    Compound: 1
    Inhibition of CXCR1 Lys99Ala mutant transfected in mouse L1.2 cells assessed as inhibition of CXCL8-induced cell migration pretreated for 15 mins measured after 4 hrs
    Inhibition of CXCR1 Lys99Ala mutant transfected in mouse L1.2 cells assessed as inhibition of CXCL8-induced cell migration pretreated for 15 mins measured after 4 hrs
    [PMID: 19560921]
    RAW264.7 IC50
    10.18 μM
    Compound: Diclofenac
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA
    [PMID: 37611534]
    RAW264.7 IC50
    10.45 μM
    Compound: Diclofenac
    Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method
    Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method
    [PMID: 37182334]
    RAW264.7 IC50
    19.59 μM
    Compound: Diclofenac
    Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of IL-6 production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method
    Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of IL-6 production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method
    [PMID: 37182334]
    RAW264.7 IC50
    21.34 μM
    Compound: Diclofenac
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA
    [PMID: 37611534]
    RAW264.7 IC50
    25.34 μM
    Compound: Diclofenac
    Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by DAF-FM staining based assay
    Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by DAF-FM staining based assay
    [PMID: 37182334]
    RAW264.7 IC50
    26.26 μM
    Compound: Diclofenac
    Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of ROS production by DCFH-DA staining based assay
    Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of ROS production by DCFH-DA staining based assay
    [PMID: 37182334]
    RAW264.7 IC50
    50.08 μM
    Compound: Diclofenac
    Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA probe based fluorescence analysis
    Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA probe based fluorescence analysis
    [PMID: 37611534]
    RAW264.7 IC50
    54.66 μM
    Compound: Diclofenac
    Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by fluorescence microscopic analysis
    Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by fluorescence microscopic analysis
    [PMID: 37611534]
    Sf21 IC50
    23.62 μM
    Compound: Diclofenac
    Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell
    Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell
    [PMID: 20974503]
    Sf9 IC50
    0.03 μM
    Compound: diclofenac
    Inhibition of human COX1 expressed in sf9 cells
    Inhibition of human COX1 expressed in sf9 cells
    [PMID: 16252917]
    Sf9 IC50
    0.07 μM
    Compound: diclofenac
    Inhibition of human COX2 expressed in sf9 cells
    Inhibition of human COX2 expressed in sf9 cells
    [PMID: 16252917]
    THP-1 IC50
    143 μM
    Compound: Diclofenac
    Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation
    Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation
    [PMID: 30818268]
    THP-1 IC50
    4.86 μM
    Compound: Diclofenac
    Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages preincubated for 6 hrs followed by PMA stimulation by phase contrast microscopic method
    Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages preincubated for 6 hrs followed by PMA stimulation by phase contrast microscopic method
    [PMID: 29289887]
    Ventricular myocyte IC50
    12.89 μM
    Compound: Diclofenac
    Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes
    Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes
    [PMID: 22761000]
    In Vitro

    Diclofenac effectively blocks COX-1 mediated prostanoid production from U937 cell microsomes, with an IC50 of 7±3 nM[1].
    Diclofenac (1-60 μM; 1 day) induces neural stem cells (NSCs)death in a concentration-dependent manner[3].
    Diclofenac (10-60 μM; 6 hours) increases the expression of cleaved (activated) caspase-3[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[3]

    Cell Line: Neural stem cells (NSCs)
    Concentration: 1, 3, 10, 30, 60 μM
    Incubation Time: 1 day
    Result: Induction of cell death was concentration-dependent and the effect was not saturated at a concentration of up to 60 μM.

    Western Blot Analysis[3]

    Cell Line: Neural stem cells (NSCs)
    Concentration: 10, 30 or 60 μM
    Incubation Time: 6 hours
    Result: The activation of caspase-3 was increased in a concentration-dependent manner.
    In Vivo

    Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal 51Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days[1].
    Diclofenac (10 mg/kg; administered via oral route just prior to induction of inflammation) shows in vivo anti-inflammatory activity in Wistar rats[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male Sprague-Dawley rats (150±200 g)[1]
    Dosage: 3 mg/kg
    Administration: Oral administration, b.i.d., for 5 days
    Result: Resulted in a significant increase in faecal 51Cr excretion.
    Animal Model: Wistar rats (150-175 g) bearing Formalin-induced rat foot paw edema model[2]
    Dosage: 10 mg/kg
    Administration: Administered via oral route just prior to induction of inflammation
    Result: Showed in vivo anti-inflammatory activity (% edema inhibition=29.2, 1 h; 22.2, 3 h; 20, 6 h).
    Molecular Weight

    296.15

    Formula

    C14H11Cl2NO2

    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    O=C(O)CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 125 mg/mL (422.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.3767 mL 16.8833 mL 33.7667 mL
    5 mM 0.6753 mL 3.3767 mL 6.7533 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (7.02 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.08 mg/mL (7.02 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.92%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.3767 mL 16.8833 mL 33.7667 mL 84.4167 mL
    5 mM 0.6753 mL 3.3767 mL 6.7533 mL 16.8833 mL
    10 mM 0.3377 mL 1.6883 mL 3.3767 mL 8.4417 mL
    15 mM 0.2251 mL 1.1256 mL 2.2511 mL 5.6278 mL
    20 mM 0.1688 mL 0.8442 mL 1.6883 mL 4.2208 mL
    25 mM 0.1351 mL 0.6753 mL 1.3507 mL 3.3767 mL
    30 mM 0.1126 mL 0.5628 mL 1.1256 mL 2.8139 mL
    40 mM 0.0844 mL 0.4221 mL 0.8442 mL 2.1104 mL
    50 mM 0.0675 mL 0.3377 mL 0.6753 mL 1.6883 mL
    60 mM 0.0563 mL 0.2814 mL 0.5628 mL 1.4069 mL
    80 mM 0.0422 mL 0.2110 mL 0.4221 mL 1.0552 mL
    100 mM 0.0338 mL 0.1688 mL 0.3377 mL 0.8442 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Diclofenac
    Cat. No.:
    HY-15036
    Quantity:
    MCE Japan Authorized Agent: